SAB Biotherapeutics, Inc. (SABS) News
Follow SAB Biotherapeutics, Inc. (SABS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
SABS pivotal study for SAB-142 advances; enrollment due Q4 2026
SafetyGUARD pivotal study for SAB-142 is on track, with last patient enrollment expected in Q4 2026 and top-line data in the second half of 2027. The company says it is funded through 2028.
MACRO | Sep 10, 2026, 04:41 PM UTC
L
SAB Biotherapeutics to take part in upcoming investor conferences
SAB Biotherapeutics, Inc. (Nasdaq: SABS) said members of its management team will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:37 PM UTC
M
SABS: Barclays Initiates Overweight
Barclays initiates coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13
EQUITY | Jun 24, 2026, 06:50 PM UTC